French biotech stock soars 31% after new data on experimental medicine

When Abivax released new trial data on its bowel disease drug obefazimod, the stock market made its verdict clear. Shares of the French biotech surged thirty-one percent Tuesday, signaling investor enthusiasm for the treatment's development path. According to CNBC, the data supported the company's clinical approach to inflammatory bowel disease, a condition affecting millions worldwide.

Listen to this story

Hear this and more stories in a personalized audio briefing.

Open The Chonkerton